Abstract
Antimalarial drug resistance is an evolving global health security threat to malaria control. Early detection of Plasmodium falciparum resistance through therapeutic efficacy studies and associated genetic analyses may facilitate timely implementation of intervention strategies. The US President’s Malaria Initiative–supported Antimalarial Resistance Monitoring in Africa Network has assisted numerous laboratories in partner countries in acquiring the knowledge and capability to independently monitor for molecular markers of antimalarial drug resistance.
Highlights
Substantial recent progress has been made in malaria control, in sub-Saharan Africa
Another development is the growing availability of oral artemisinin-based combination therapies (ACTs), which rely on an artemisinin plus a longer-acting partner drug from another class to treat uncomplicated malaria [2]
During 2005–2015, the Global Fund to Fight AIDS, TB, and Malaria supplied an additional 582 million treatments [11]. Losing these medications to drug resistance would jeopardize the progress achieved in reducing malaria infections in recent years and threaten global health security by putting millions of additional persons at risk for death from malaria
Summary
Substantial recent progress has been made in malaria control, in sub-Saharan Africa. Losing these medications to drug resistance would jeopardize the progress achieved in reducing malaria infections in recent years and threaten global health security by putting millions of additional persons at risk for death from malaria.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
